559 related articles for article (PubMed ID: 24711661)
1. Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease.
Spoerl S; Mathew NR; Bscheider M; Schmitt-Graeff A; Chen S; Mueller T; Verbeek M; Fischer J; Otten V; Schmickl M; Maas-Bauer K; Finke J; Peschel C; Duyster J; Poeck H; Zeiser R; von Bubnoff N
Blood; 2014 Jun; 123(24):3832-42. PubMed ID: 24711661
[TBL] [Abstract][Full Text] [Related]
2. Novel JAK Inhibitors to Reduce Graft-Versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation in a Preclinical Mouse Model.
Kim S; Ruminski P; Singh M; Staser K; Ashami K; Ritchey J; Lim S; DiPersio JF; Choi J
Molecules; 2024 Apr; 29(8):. PubMed ID: 38675621
[TBL] [Abstract][Full Text] [Related]
3. Preclinical evaluation of JAK1/2 inhibition by ruxolitinib in a murine model of chronic graft-versus-host disease.
Ryu DB; Lim JY; Kim TW; Shin S; Lee SE; Park G; Min CK
Exp Hematol; 2021 Jun; 98():36-46.e2. PubMed ID: 33811972
[TBL] [Abstract][Full Text] [Related]
4. Pharmacologic Inhibition of JAK1/JAK2 Signaling Reduces Experimental Murine Acute GVHD While Preserving GVT Effects.
Carniti C; Gimondi S; Vendramin A; Recordati C; Confalonieri D; Bermema A; Corradini P; Mariotti J
Clin Cancer Res; 2015 Aug; 21(16):3740-9. PubMed ID: 25977345
[TBL] [Abstract][Full Text] [Related]
5. Ruxolitinib, a JAK1/JAK2 selective inhibitor, ameliorates acute and chronic steroid-refractory GvHD mouse models.
Huarte E; Peel M; Juvekar A; Dubé P; Sarah S; Stephens L; Stewart B; Long B; Czerniak P; Oliver J; Smith P
Immunotherapy; 2021 Aug; 13(12):977-987. PubMed ID: 34184542
[No Abstract] [Full Text] [Related]
6. Pharmacologic blockade of JAK1/JAK2 reduces GvHD and preserves the graft-versus-leukemia effect.
Choi J; Cooper ML; Alahmari B; Ritchey J; Collins L; Holt M; DiPersio JF
PLoS One; 2014; 9(10):e109799. PubMed ID: 25289677
[TBL] [Abstract][Full Text] [Related]
7. Ruxolitinib in steroid refractory graft-vs.-host disease: a case report.
Maffini E; Giaccone L; Festuccia M; Brunello L; Buondonno I; Ferrero D; Boccadoro M; Dellacasa C; Busca A; Novero D; Bruno B
J Hematol Oncol; 2016 Aug; 9(1):67. PubMed ID: 27502249
[TBL] [Abstract][Full Text] [Related]
8. Janus kinase inhibition in the treatment and prevention of graft-versus-host disease.
De Togni E; Cole O; Abboud R
Front Immunol; 2024; 15():1304065. PubMed ID: 38380328
[TBL] [Abstract][Full Text] [Related]
9. Ruxolitinib treatment for steroid refractory acute and chronic graft vs host disease in children: Clinical and immunological results.
González Vicent M; Molina B; González de Pablo J; Castillo A; Díaz MÁ
Am J Hematol; 2019 Mar; 94(3):319-326. PubMed ID: 30536806
[TBL] [Abstract][Full Text] [Related]
10. Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628).
von Bubnoff N; Ihorst G; Grishina O; Röthling N; Bertz H; Duyster J; Finke J; Zeiser R
BMC Cancer; 2018 Nov; 18(1):1132. PubMed ID: 30453910
[TBL] [Abstract][Full Text] [Related]
11. BET Bromodomain Inhibitors Which Permit Treg Function Enable a Combinatorial Strategy to Suppress GVHD in Pre-clinical Allogeneic HSCT.
Copsel SN; Lightbourn CO; Barreras H; Lohse I; Wolf D; Bader CS; Manov J; Kale BJ; Shah D; Brothers SP; Perez VL; Komanduri KV; Wahlestedt C; Levy RB
Front Immunol; 2018; 9():3104. PubMed ID: 30733722
[TBL] [Abstract][Full Text] [Related]
12. TAK1 inhibition ameliorates survival from graft-versus-host disease in an allogeneic murine marrow transplantation model.
Kobayashi A; Kobayashi S; Miyai K; Osawa Y; Horiuchi T; Kato S; Maekawa T; Yamamura T; Watanabe J; Sato K; Tsuda H; Kimura F
Int J Hematol; 2018 Feb; 107(2):222-229. PubMed ID: 29027124
[TBL] [Abstract][Full Text] [Related]
13. Ruxolitinib for steroid-refractory graft versus host disease in pediatric HSCT: high response rate and manageable toxicity.
Mozo Y; Bueno D; Sisinni L; Fernández-Arroyo A; Rosich B; Martínez AP; Benítez-Carabante MI; Alonso L; Uría ML; Heredia CD; Mestre-Duran C; Pascual CFB; Torres J; Losantos I; Escudero A; Ruz-Caracuel B
Pediatr Hematol Oncol; 2021 May; 38(4):331-345. PubMed ID: 33661711
[TBL] [Abstract][Full Text] [Related]
14. Early Notch Signals Induce a Pathogenic Molecular Signature during Priming of Alloantigen-Specific Conventional CD4
Chung J; Radojcic V; Perkey E; Parnell TJ; Niknafs Y; Jin X; Friedman A; Labrecque N; Blazar BR; Brennan TV; Siebel CW; Maillard I
J Immunol; 2019 Jul; 203(2):557-568. PubMed ID: 31182480
[TBL] [Abstract][Full Text] [Related]
15. Blockade of TIM-1 on the donor graft ameliorates graft-versus-host disease following hematopoietic cell transplantation.
Iliopoulou BP; Hsu K; Pérez-Cruz M; Tang SW; Pang WW; Erkers T; Kambham N; Freeman GJ; Dekruyff RH; Meyer EH
Blood Adv; 2019 Nov; 3(21):3419-3431. PubMed ID: 31714958
[TBL] [Abstract][Full Text] [Related]
16. Ruxolitinib: a potential treatment for corticosteroid refractory acute graft-versus-host disease.
Abedin SM; Hamadani M
Expert Opin Investig Drugs; 2020 May; 29(5):423-427. PubMed ID: 32293938
[TBL] [Abstract][Full Text] [Related]
17. Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey.
Zeiser R; Burchert A; Lengerke C; Verbeek M; Maas-Bauer K; Metzelder SK; Spoerl S; Ditschkowski M; Ecsedi M; Sockel K; Ayuk F; Ajib S; de Fontbrune FS; Na IK; Penter L; Holtick U; Wolf D; Schuler E; Meyer E; Apostolova P; Bertz H; Marks R; Lübbert M; Wäsch R; Scheid C; Stölzel F; Ordemann R; Bug G; Kobbe G; Negrin R; Brune M; Spyridonidis A; Schmitt-Gräff A; van der Velden W; Huls G; Mielke S; Grigoleit GU; Kuball J; Flynn R; Ihorst G; Du J; Blazar BR; Arnold R; Kröger N; Passweg J; Halter J; Socié G; Beelen D; Peschel C; Neubauer A; Finke J; Duyster J; von Bubnoff N
Leukemia; 2015 Oct; 29(10):2062-8. PubMed ID: 26228813
[TBL] [Abstract][Full Text] [Related]
18. Efficiency and Toxicity of Ruxolitinib as a Salvage Treatment for Steroid-Refractory Chronic Graft-Versus-Host Disease.
Wang D; Liu Y; Lai X; Chen J; Cheng Q; Ma X; Lin Z; Wu D; Xu Y
Front Immunol; 2021; 12():673636. PubMed ID: 34276662
[TBL] [Abstract][Full Text] [Related]
19. Kinase Inhibition as Treatment for Acute and Chronic Graft-
Braun LM; Zeiser R
Front Immunol; 2021; 12():760199. PubMed ID: 34868001
[TBL] [Abstract][Full Text] [Related]
20. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]